No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - Report from the ItalKid Project database

Gianluigi Ardissino, Sara Vigaǹo, Sara Testa, Valeria Daccò, Fabio Paglialonga, Antonio Leoni, Mirco Belingheri, Luigi Avolio, Antonio Ciofani, Aldo Claris-Appiani, Daniele Cusi, Alberto Edefonti, Anita Ammenti, Milva Cecconi, Carmelo Fede, Luciana Ghio, Angela La Manna, Silvio Maringhini, Teresa Papalia, Ivana PelaLorena Pisanello, Ilse Maria Ratsch

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background. Chronic kidney diseases (CKD) tend to progress to end-stage renal failure (ESRF). As it has been demonstrated that angiotensin-converting enzyme inhibitors (ACEi) have a renoprotective effect in adults with proteinuric disease and may be effective in reducing hyperfiltration and proteinuria, they are also frequently used as anti-progression agents in paediatric patients with CKD despite the lack of data confirming their role in the nephropathies peculiar to children. The aim of this study was to investigate whether patients with hypodysplastic CKD (the most common cause of ESRF in children) treated with ACEi show a significantly slower decline in creatinine clearance (Ccr). Methods. The analysis was based on the information available in the database of the ItalKid Project, a nationwide, population-based registry of chronic renal insufficiency (CRI) in children in Italy. Of the 822 patients with CRI due to hypodysplasia, we selected those who had been continuously treated with ACEi; the control patients were identified from the same diagnostic group and matched for gender, age and baseline Ccr. Results. Progression was analysed as the slope of Ccr in a total of 164 patients: 41 cases and 123 matched controls. There were no significant between-group differences in blood pressure, duration of follow-up or pre-study slope of Ccr (-0.31 ± 2.26 vs - 0.33 ± 3.58 ml/min/1.73m2/year; P = NS). After an average of 4.9 ± 2.3 years, the mean slope of Ccr was 40% lower in the ACEi-treated cases in comparison to controls (-1.08 ± 2.08 vs -1.80 ± 4.42 ml/min/1.73m2/year), however, this difference was not statistically significant (P = 0.31). Conclusions. We conclude that ACEi treatment does not significantly modify the naturally progressive course of hypodysplastic nephropathy in children and further studies are necessary before such treatment is routinely proposed for anti-progression purposes in children with CKD.

Original languageEnglish
Pages (from-to)2525-2530
Number of pages6
JournalNephrology Dialysis Transplantation
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Databases
Creatinine
Chronic Kidney Failure
Proteinuria
Italy
Registries
Research Design
Pediatrics
Blood Pressure
Therapeutics
Population

Keywords

  • Angiotensin-converting enzyme inhibitors
  • Chronic kidney diseases
  • Paediatric nephrology
  • Progression

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - Report from the ItalKid Project database. / Ardissino, Gianluigi; Vigaǹo, Sara; Testa, Sara; Daccò, Valeria; Paglialonga, Fabio; Leoni, Antonio; Belingheri, Mirco; Avolio, Luigi; Ciofani, Antonio; Claris-Appiani, Aldo; Cusi, Daniele; Edefonti, Alberto; Ammenti, Anita; Cecconi, Milva; Fede, Carmelo; Ghio, Luciana; La Manna, Angela; Maringhini, Silvio; Papalia, Teresa; Pela, Ivana; Pisanello, Lorena; Ratsch, Ilse Maria.

In: Nephrology Dialysis Transplantation, Vol. 22, No. 9, 09.2007, p. 2525-2530.

Research output: Contribution to journalArticle

Ardissino, G, Vigaǹo, S, Testa, S, Daccò, V, Paglialonga, F, Leoni, A, Belingheri, M, Avolio, L, Ciofani, A, Claris-Appiani, A, Cusi, D, Edefonti, A, Ammenti, A, Cecconi, M, Fede, C, Ghio, L, La Manna, A, Maringhini, S, Papalia, T, Pela, I, Pisanello, L & Ratsch, IM 2007, 'No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - Report from the ItalKid Project database', Nephrology Dialysis Transplantation, vol. 22, no. 9, pp. 2525-2530. https://doi.org/10.1093/ndt/gfm237
Ardissino, Gianluigi ; Vigaǹo, Sara ; Testa, Sara ; Daccò, Valeria ; Paglialonga, Fabio ; Leoni, Antonio ; Belingheri, Mirco ; Avolio, Luigi ; Ciofani, Antonio ; Claris-Appiani, Aldo ; Cusi, Daniele ; Edefonti, Alberto ; Ammenti, Anita ; Cecconi, Milva ; Fede, Carmelo ; Ghio, Luciana ; La Manna, Angela ; Maringhini, Silvio ; Papalia, Teresa ; Pela, Ivana ; Pisanello, Lorena ; Ratsch, Ilse Maria. / No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - Report from the ItalKid Project database. In: Nephrology Dialysis Transplantation. 2007 ; Vol. 22, No. 9. pp. 2525-2530.
@article{0eb938a748334d76b05368d6a518a1e0,
title = "No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - Report from the ItalKid Project database",
abstract = "Background. Chronic kidney diseases (CKD) tend to progress to end-stage renal failure (ESRF). As it has been demonstrated that angiotensin-converting enzyme inhibitors (ACEi) have a renoprotective effect in adults with proteinuric disease and may be effective in reducing hyperfiltration and proteinuria, they are also frequently used as anti-progression agents in paediatric patients with CKD despite the lack of data confirming their role in the nephropathies peculiar to children. The aim of this study was to investigate whether patients with hypodysplastic CKD (the most common cause of ESRF in children) treated with ACEi show a significantly slower decline in creatinine clearance (Ccr). Methods. The analysis was based on the information available in the database of the ItalKid Project, a nationwide, population-based registry of chronic renal insufficiency (CRI) in children in Italy. Of the 822 patients with CRI due to hypodysplasia, we selected those who had been continuously treated with ACEi; the control patients were identified from the same diagnostic group and matched for gender, age and baseline Ccr. Results. Progression was analysed as the slope of Ccr in a total of 164 patients: 41 cases and 123 matched controls. There were no significant between-group differences in blood pressure, duration of follow-up or pre-study slope of Ccr (-0.31 ± 2.26 vs - 0.33 ± 3.58 ml/min/1.73m2/year; P = NS). After an average of 4.9 ± 2.3 years, the mean slope of Ccr was 40{\%} lower in the ACEi-treated cases in comparison to controls (-1.08 ± 2.08 vs -1.80 ± 4.42 ml/min/1.73m2/year), however, this difference was not statistically significant (P = 0.31). Conclusions. We conclude that ACEi treatment does not significantly modify the naturally progressive course of hypodysplastic nephropathy in children and further studies are necessary before such treatment is routinely proposed for anti-progression purposes in children with CKD.",
keywords = "Angiotensin-converting enzyme inhibitors, Chronic kidney diseases, Paediatric nephrology, Progression",
author = "Gianluigi Ardissino and Sara Vigaǹo and Sara Testa and Valeria Dacc{\`o} and Fabio Paglialonga and Antonio Leoni and Mirco Belingheri and Luigi Avolio and Antonio Ciofani and Aldo Claris-Appiani and Daniele Cusi and Alberto Edefonti and Anita Ammenti and Milva Cecconi and Carmelo Fede and Luciana Ghio and {La Manna}, Angela and Silvio Maringhini and Teresa Papalia and Ivana Pela and Lorena Pisanello and Ratsch, {Ilse Maria}",
year = "2007",
month = "9",
doi = "10.1093/ndt/gfm237",
language = "English",
volume = "22",
pages = "2525--2530",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy - Report from the ItalKid Project database

AU - Ardissino, Gianluigi

AU - Vigaǹo, Sara

AU - Testa, Sara

AU - Daccò, Valeria

AU - Paglialonga, Fabio

AU - Leoni, Antonio

AU - Belingheri, Mirco

AU - Avolio, Luigi

AU - Ciofani, Antonio

AU - Claris-Appiani, Aldo

AU - Cusi, Daniele

AU - Edefonti, Alberto

AU - Ammenti, Anita

AU - Cecconi, Milva

AU - Fede, Carmelo

AU - Ghio, Luciana

AU - La Manna, Angela

AU - Maringhini, Silvio

AU - Papalia, Teresa

AU - Pela, Ivana

AU - Pisanello, Lorena

AU - Ratsch, Ilse Maria

PY - 2007/9

Y1 - 2007/9

N2 - Background. Chronic kidney diseases (CKD) tend to progress to end-stage renal failure (ESRF). As it has been demonstrated that angiotensin-converting enzyme inhibitors (ACEi) have a renoprotective effect in adults with proteinuric disease and may be effective in reducing hyperfiltration and proteinuria, they are also frequently used as anti-progression agents in paediatric patients with CKD despite the lack of data confirming their role in the nephropathies peculiar to children. The aim of this study was to investigate whether patients with hypodysplastic CKD (the most common cause of ESRF in children) treated with ACEi show a significantly slower decline in creatinine clearance (Ccr). Methods. The analysis was based on the information available in the database of the ItalKid Project, a nationwide, population-based registry of chronic renal insufficiency (CRI) in children in Italy. Of the 822 patients with CRI due to hypodysplasia, we selected those who had been continuously treated with ACEi; the control patients were identified from the same diagnostic group and matched for gender, age and baseline Ccr. Results. Progression was analysed as the slope of Ccr in a total of 164 patients: 41 cases and 123 matched controls. There were no significant between-group differences in blood pressure, duration of follow-up or pre-study slope of Ccr (-0.31 ± 2.26 vs - 0.33 ± 3.58 ml/min/1.73m2/year; P = NS). After an average of 4.9 ± 2.3 years, the mean slope of Ccr was 40% lower in the ACEi-treated cases in comparison to controls (-1.08 ± 2.08 vs -1.80 ± 4.42 ml/min/1.73m2/year), however, this difference was not statistically significant (P = 0.31). Conclusions. We conclude that ACEi treatment does not significantly modify the naturally progressive course of hypodysplastic nephropathy in children and further studies are necessary before such treatment is routinely proposed for anti-progression purposes in children with CKD.

AB - Background. Chronic kidney diseases (CKD) tend to progress to end-stage renal failure (ESRF). As it has been demonstrated that angiotensin-converting enzyme inhibitors (ACEi) have a renoprotective effect in adults with proteinuric disease and may be effective in reducing hyperfiltration and proteinuria, they are also frequently used as anti-progression agents in paediatric patients with CKD despite the lack of data confirming their role in the nephropathies peculiar to children. The aim of this study was to investigate whether patients with hypodysplastic CKD (the most common cause of ESRF in children) treated with ACEi show a significantly slower decline in creatinine clearance (Ccr). Methods. The analysis was based on the information available in the database of the ItalKid Project, a nationwide, population-based registry of chronic renal insufficiency (CRI) in children in Italy. Of the 822 patients with CRI due to hypodysplasia, we selected those who had been continuously treated with ACEi; the control patients were identified from the same diagnostic group and matched for gender, age and baseline Ccr. Results. Progression was analysed as the slope of Ccr in a total of 164 patients: 41 cases and 123 matched controls. There were no significant between-group differences in blood pressure, duration of follow-up or pre-study slope of Ccr (-0.31 ± 2.26 vs - 0.33 ± 3.58 ml/min/1.73m2/year; P = NS). After an average of 4.9 ± 2.3 years, the mean slope of Ccr was 40% lower in the ACEi-treated cases in comparison to controls (-1.08 ± 2.08 vs -1.80 ± 4.42 ml/min/1.73m2/year), however, this difference was not statistically significant (P = 0.31). Conclusions. We conclude that ACEi treatment does not significantly modify the naturally progressive course of hypodysplastic nephropathy in children and further studies are necessary before such treatment is routinely proposed for anti-progression purposes in children with CKD.

KW - Angiotensin-converting enzyme inhibitors

KW - Chronic kidney diseases

KW - Paediatric nephrology

KW - Progression

UR - http://www.scopus.com/inward/record.url?scp=34548167909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548167909&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfm237

DO - 10.1093/ndt/gfm237

M3 - Article

C2 - 17526542

AN - SCOPUS:34548167909

VL - 22

SP - 2525

EP - 2530

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 9

ER -